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Due to the high number of drug-resistant HIV-1 mutants generated by highly active antiretroviral
therapy (HAART), there is continuing demand for new types of inhibitors. Both the assembly of the Gag
polyprotein into immature and mature HIV-1 particles are attractive candidates for the blocking of the
retroviral life cycle. Currently, no therapeutically-used assembly inhibitor is available. One possible
explanation is the lack of a reliable and simple assembly inhibitor screening method.
To identify compounds potentially inhibiting the formation of both types of HIV-1 particles, we
developed a new ﬂuorescent high-throughput screening assay. This assay is based on the quantiﬁcation
of the assembly efﬁciency in vitro in a 96-well plate format. The key components of the assay are HIV-1
Gag-derived proteins and a dual-labelled oligonucleotide, which emits ﬂuorescence only when the
assembly of retroviral particles is inhibited. The method was validated using three (CAI, BM2, PF74)
reported assembly inhibitors.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The current therapy for HIV-infected patients is mainly based
on a combination of inhibitors of viral enzymes i.e. reverse tran-
scriptase, protease and integrase or viral entry. Presently, 26 FDA
approved anti-HIV drugs are available: seven nucleoside reverse
transcriptase inhibitors (NRTIs), one nucleotide reverse tran-
scriptase inhibitor (NtRTI), four non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), 10 protease inhibitors (PIs), two
integrase inhibitors (INIs), one fusion inhibitor, and one co-
receptor inhibitor (De Clercq, 2010) (http://www.fda.gov).
Despite the positive results from highly active antiretroviral ther-
apy (HAART), there is continuing demand for new types of com-
pounds that would help to overcome tolerance problems and more
importantly, the emergence of high numbers of drug-resistant
mutants generated by the error-prone reverse transcriptase and
their selection in the presence of a particular inhibitor.
Similarly to other retroviruses, HIV-1 creates its infectious
particles in two independent steps. In the ﬁrst, the structural
polyprotein Gag assembles at the plasma membrane and theInc. This is an open access article u
28 Prague, Czech Republic.
Rumlová),resulting immature spherical particle buds from the cell. Viral
protease is activated during the budding and cleaves the Gag
polyprotein to yield MA, CA, and NC proteins that reassemble to
form a mature, fully infectious virion. The MA protein remains
associated with the viral envelope, while the mature CA assembles
into a conical shell surrounding the condensed ribonucleoprotein
complex of the NC protein and the viral RNA. Both the formation of
the immature particle and the mature core are critical steps in the
virus life cycle and the prevention of the interactions mediating
these processes blocks the infectivity.
Although the virus assembly is an attractive candidate for
inhibition, no suitable assembly inhibitor is currently available.
Attempts to develop inhibitors interfering with the assembly
yielded several compounds binding to CA, suggesting that CA may
be a viable drug target. These compounds include: small-molecule
inhibitors CAP-1 (Tang et al., 2003; Kelly et al., 2007), PF-74 (Blair
et al., 2010), benzodiazepine derived compounds (BDs), benzimi-
dazole derived compounds (BMs) (Lemke et al., 2012), and peptide
inhibitor CAI (Sticht et al., 2005; Ternois et al., 2005). Another class
of promising inhibitors are compounds blocking HIV maturation
by inhibiting CA-SP1 cleavage, among them is PA-457 (bevirimat)
(Li et al., 2003; Fujioka et al., 1994; Kanamoto et al., 2001; Zhou et
al., 2004) and PF-46396 (Blair et al., 2009; Waki et al., 2012).
A number of studies have demonstrated that both assembly of
an immature virus-like particle and a mature core can be per-
formed in vitro from puriﬁed recombinant Gag-derived proteinsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
R. Hadravová et al. / Virology 486 (2015) 78–87 79(Campbell and Vogt, 1995; Campbell and Rein, 1999; Ehrlich et al.,
1992; Gross et al., 1997, 2000; Klikova et al., 1995; Rumlova-
Klikova et al., 2000). HIV-1 Gag-derived proteins (e.g. CA and
CANC) that assemble in vitro into narrow tubular and conical
structures have a mature-like arrangement of CA (Campbell and
Vogt, 1995; Ehrlich et al., 1992; Gross et al., 1997, 1998; Ganser et
al., 1999; Li et al., 2000; von Schwedler et al., 1998; Bharat et al.,Fig. 1. In vitro assembly of CANC (A–C) and ΔMACANCSP2 (D–F). A, D: coomassie blue-stai
0.5 mg/ml, lane 3: 2.5 mg/ml; (D) ΔMACANCSP2: lane 1: 0.05 mg/ml, lane 2: 0.5 mg/ml
assembled in vitro: by dialysis against the assembly buffer containing 0.1 M NaCl: (B) C
(C) CANC, (F) ΔMACANCSP2; G. Sequence of tqON used for the in vitro assembly of HIV-1 C
Gag and it is modiﬁed by FAM (at 30 end) and BHQ1 at the eighth residue (designed dT2014). In contrast, HIV-1 Gag derivatives known to assemble into
spherical structures adopt an immature-like arrangement (Gross
et al., 2000; von Schwedler et al., 1998; Bharat et al., 2014). The
virus-like particle's in vitro assembly technique is a well-deﬁned
process based on the mixing of individual functional components
(i.e. puriﬁed recombinant Gag-derived protein and an optional
nucleic acid) and controlled adjustment of solvent conditions,ned SDS-polyacrylamide gel of puriﬁed (A) HIV-1 CANC: lane 1: 0.05 mg/ml, lane 2:
, lane 3: 2.5 mg/ml. B–F: representative TEM images of negatively stained particles
ANC, (E) ΔMACANCSP2; by dilution to the assembly buffer containing 0.3 M NaCl
ANC and ΔMACANCSP2. The tqON sequence is derived from the 30 terminus of HIV-
) upstream from the 30 end. Bar represents 100 nm.
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analyzed by electron microscopy. Apart from the cell-based assays
quantifying the HIV-1 p24 antigen released from the infected cells
exposed to tested compounds (Blair et al., 2009), several high-
throughput screening assays based on the in vitro assembly of HIV-
1 Gag derived proteins were published. Among them the turbidi-
metric assay for the quantitative monitoring of the rate of HIV-1
CA assembly and the immobilized capsid assembly assay (Lemke
et al., 2012) have been described.
Here, we report the development of a Fast Assembly Inhibitor
Test for HIV (FAITH). This method is based on the quantitation of
assembly efﬁciency in vitro of both spherical and tubular HIV-1
particles formed from puriﬁed Gag-derived ΔMACANCSP2 and
CANC proteins, respectively. The method was evaluated using
inhibitors: CAI (Sticht et al., 2005), BM2 (Lemke et al., 2012), PF-
074 (Blair et al., 2010), which were demonstrated to block retro-
viral assembly by targeting the different domains of Gag. The main
advantages of our ﬂuorescent method are i) it is a method for
testing the assembly inhibitors in microtitre format solutions
under physiological conditions; ii) it is sensitive, quantitative and
fast; iii) it is simple and does not require any washing steps, and
iv) it is not affected with DMSO up to ﬁnal concentration of 1%.Results
In vitro assembly of HIV-1 Gag-derived proteins by dilution
During its life cycle, HIV-1 subsequently assembles two types of
particles, the immature and the mature one. It was shown that the
interactions among the CA proteins, which stabilize the immature
and mature viruses, are almost completely distinct (Bharat et al.,
2012; Schur et al., 2015). HIV-1 Gag-derived proteins that assem-
ble the spherical particles adopt immature-like arrays, while those
assembled into tubular particles adopt a mature-like arrangement
(Bharat et al., 2014). The in vitro assembly of the spherical particles
was described for the Gag-derived protein lacking a p6 protein and
amino acids 16-99 of the MA protein (ΔMACANCSP2) (Gross et al.,
2000). The detailed cryo-EM study of the in vitro assembled
spherical particles from the ΔMACANCSP2 protein revealed the
same inner organization as that observed for the immature virions
(Gross et al., 2000). The formation of mature-like tubular particles
in vitro can be achieved using CA or CA-NC proteins (Campbell and
Vogt, 1995; Ehrlich et al., 1992; Gross et al., 1997). The structural
organization, in these tubular particles, resembles the arrange-
ment observed in the mature conical cores (Li et al., 2000; Briggs
et al., 2003). To increase the applicability of our assay on the
assembly of both immature virus and mature core, we used two
proteins: CANC for the formation of mature-like tubular particles
and ΔMACANCSP2 for the formation of immature-like spherical
particles (for the protein purity, see Fig. 1A and D, respectively).
The in vitro assembly of the retroviral particles is usually per-
formed by mixing the stock solution of puriﬁed Gag-derived
protein with an appropriate buffer, with optional nucleic acids,
and by dialyzing this mixture against an assembly buffer (Camp-
bell and Vogt, 1995; Gross et al., 1997; Klikova et al., 1995; Ulbrich
et al., 2006). Since the dialysis step prevents a high-throughput
screening, we used for the in vitro assembly a diluting method, in
which we diluted the stock solution of either the CANC or ΔMA-
CANCSP2 proteins into the assembly buffer containing oligonu-
cleotides. To achieve the most effective in vitro assembly in the 96-
well plate format, we optimized the conditions for the formation
of both types of the particles. With an attempt to maximally mimic
the physiological conditions, we focused on pH and ionic strength
of the assembly buffer, on the protein to nucleic acid ratios and the
size of the nucleic acid. The comparable yield of assembledstructures to that obtained by the above mentioned dialysis
method was achieved by dilution method using 18 μM CANC or
15 μM ΔMACANCSP2 at the protein to ON ratio at 10:1, at pH
8.0 in 300 mM NaCl (compare Fig. 1B, C and E, F). As neither the
length nor the sequence of tested single-stranded DNA oligonu-
cleotides signiﬁcantly affected the efﬁciency of the dilution
mediated assembly, the 40-meric sequence derived from the 30
terminus of HIV-1 Gag was chosen (Fig. 1G). No assembled parti-
cles were observed by transmission electron microscopy in the
control samples, containing only CANC or ΔMACANCSP2 proteins
without the addition of the oligonucleotide (data not shown).
FAITH principle
The quantiﬁcation of the assembly efﬁciency using FAITH is
based on the use of a dual-labelled oligonucleotide (tqON). The
tqON molecule is a single-stranded DNA oligonucleotide with a
reporter dye-ﬂuorescein (FAM) attached at its 30 terminus and a
quencher molecule-Black Hole Quencher (BHQ), which blocks the
FAM ﬂuorescence emission and it is attached to the eighth residue
(designed dT) upstream from the 30 end (Fig. 1G).
The in vitro assembly is triggered by the dilution of the stock
solutions of puriﬁed CANC or ΔMACANCSP2 proteins to the
assembly buffer and by the addition of tqON. During three-hour
incubation, a certain amount of tqON is bound to the NC domain
and packaged into the forming particles. Consequently, Exonu-
clease I (ExoI), that degrades tqON in a 30-50 direction, is added to
the solution and the released ﬂuorescence is measured. The tqON
molecules wrapped in the assembled particles are protected by a
protein shell against the ExoI cleavage. These intact tqON do not
emit any ﬂuorescence in contrast to the unprotected (unbound)
portion of tqON, which is readily degraded by ExoI. The degrada-
tion of tqON results in the separation of the FAM quencher from
the reporter BHQ molecule and subsequently to the increment of
emitted ﬂuorescence. The difference between ﬂuorescence values
of the control sample containing only free tqON and that con-
sisting of CANC or ΔMACANCSP2 assembling in the presence of
tqON is equivalent to the amount of protected tqON and expresses
the efﬁciency of the assembly in the presence of tested inhibitor.
The positive control represents co-assembly of either CANC or
ΔMACANCSP2 with the tqON in the absence of inhibitor. Thus the
ability of compounds to block the assembly of the immature or
mature HIV-1 can be readily quantiﬁed based on the ﬂuorescence
released by the ExoI cleavage of the residual non-incorporated
tqON.
The ﬂuorescence recorded in a typical course of CANC and
ΔMACANCSP2 assembly is shown in Fig. 2A and D, respectively.
Here, the HIV-1 CANC or ΔMACANCSP2 proteins were diluted into
the assembly buffer containing tqON in a 96-well plate. After 3-h
incubation at room temperature, ExoI was added and the emitted
ﬂuorescence was continuously measured for 2 h by using a 96-
well plate reader. The other essential control experiments without
the tested inhibitors include i) a sample where only tqON in the
absence of the retroviral protein is cleaved by ExoI, and ii) a
sample where the retroviral protein is replaced with the assembly
incompetent protein (BSA). As expected, no ﬂuorescence was
detected in CANCþtqON or ΔMACANCSP2þtqON containing
samples without ExoI (Fig. 2A and D yellow curve). The addition of
ExoI to the sample lacking the retroviral proteins led to degrada-
tion of free tqON resulting in the rapid increase of ﬂuorescence
(Fig. 2A and D red curve). The addition of ExoI to the same con-
centration of tqON in a presence of either CANC or ΔMACANCSP2
signiﬁcantly reduced both the speed and the maximal yield of
ﬂuorescence emission (Fig. 2A and D blue curve) (compare Fig. 2A
and D red and blue curves). The protection of tqON by assembled
CANC or ΔMACANCSP2 is “protein speciﬁc” as documented by the
Fig. 2. Quantiﬁcation of in vitro assembly of HIV-1 CANC (A–C) and ΔMACANCSP2 (D–F) by FAITH. Fluorescence emission curves demonstrating kinetics of degradation of tqON
by ExoI in the controls and in the in vitro assembled (A) CANC and (D) ΔMACANCSP2 particles. ExoI catalysed degradation of tqON in the buffer (red curve) and in presence of
BSA (green curve), ExoI catalysed degradation of tqON incorporated into either HIV-CANC (A) or ΔMACANCSP2 (D) (blue curve), control of stability of tqON incorporated into
either HIV CANC (A) or ΔMACANCSP2 (D) in the absence of ExoI (yellow curve). B, E: TEM pictures of particles assembled in the presence of tqON and treated with ExoI CANC
(B); ΔMACANCSP2 (E). Bars represent 100 nm. C, F: average percentage of degraded tqON in the buffer containing: tqON and ExoI (C, F red columns) and in the sample
containing tqON, ExoI and either CANC or ΔMACANCSP2 (C or F blue columns, respectively).
R. Hadravová et al. / Virology 486 (2015) 78–87 81negative control sample containing BSAþtqON (Fig. 2A and D
green curve). The transmission electron microscopy (TEM) of
negatively stained samples after ﬂuorescence measurement cor-
related well with the FAITH results and conﬁrmed the formation of
tubular or spherical structures only in the samples containing
CANCþtqON (Fig. 2B) or ΔMACANCSP2þtqON (Fig. 2E), respec-
tively. TEM analysis of the control samples showed only protein
precipitates (data not shown).FAITH optimization and reproducibility
Quantiﬁcation of the assembly efﬁciency in FAITH is based on
efﬁcient quantitative incorporation of tqON into the particles,
which provides a sufﬁcient difference of the nuclease triggered
ﬂuorescence signal between samples containing free tqON
and tqON protected by the assembled protein shell. Therefore, we
studied the effect of the protein to tqON ratio on the level of
incorporated tqON. We found that the in vitro assembly occurs
R. Hadravová et al. / Virology 486 (2015) 78–8782within the range of protein:tqON wt:wt ratios from 10:0.1 to 10:2.
The desired maximal incorporation of tqON into the CANC tubes or
ΔMACANCSP2 spheres was obtained for both proteins at the
protein:tqON (wt/wt] ratio of 10:0.5 (Fig. S1), which corresponds
to molar ratios 7.5:1 and 8:1 for HIV CANC:tqON and
ΔMACANCSP2:tqON, respectively. At this ratio, the incorporation
of about 60% of the total tqON was achieved as measured within
the interval 35–60 min, after the addition of 20 units of ExoI, at theFig. 3. Quantiﬁcation of in vitro assembly of HIV-1 CANC (A–D) and ΔMACANCSP2 (E–H) by
degradation of tqON by ExoI after the in vitro assembly of (A) CANC and (E) ΔMACANCSP
of: CAI (brown curve), CAIctrl (orange curve), tqON only (red curve), (A) CANC or (E)
(A) CANC or (E) ΔMACANCSP2 CAIctrl (pink curve), and (A) CANC or (E) ΔMACANCSP2 wi
i.e. assembly of (B) CANC and (F) ΔMACANCSP2 in the presence of tqON and CAIctrl at the
e. assembly of (B) CANC and (F) ΔMACANCSP2 in the presence of tqON and CAI. 3D, H: pe
in the presence of selected inhibitors. Bar represents 100 nm.protein concentration of 18 mM for CANC and 15 mM for ΔMA-
CANCSP2 (i.e. 60 mg of protein and 3 mg of tqON in 100 ml reaction).
To validate the reproducibility of the presented method, the
proteins were repeatedly expressed in independent cultivations
and puriﬁed (CANC and ΔMACANCSP2 ﬁve and three times,
respectively), and assembled in the presence of tqON from four
independently-synthesized batches (Generi Biotech). Different
batches of the ExoI enzyme (NEB, 3x) were tested as well. ResultsFAITH in the presence of selected inhibitors. Kinetic ﬂuorescence emission curves of
2 in the presence of selected inhibitors. (3A, E): degradation of tqON in the presence
ΔMACANCSP2 and CAI (green curve), (A) CANC or (E) ΔMACANCSP2 (blue curve),
thout addition of ExoI (yellow curve). 3B, F: TEM pictures of the “pink curve” sample
molar ratio protein:inhibitor 1:2. 3C, G: TEM pictures of the “green curve” sample i.
rcentage of efﬁciency of in vitro assembled (D) CANC or (H) ΔMACANCSP2 particles
Fig. 4. TEM analysis of assembled CANC particles in the presence of indicated inhibitors. Following one-hour incubation of HIV CANC protein in the presence of indicated
inhibitors or DMSO, the mixtures were diluted to the concentration optimal for assembly, tqON was added and the incubation proceeded for three-hours at RT. Then
Exonuclease 1 and MgCl2 were added and emitted ﬂuorescence was measured by ﬂuorescence reader. 10 ml aliquots of the reaction mixture were negatively stained with 2%
phosphotungstic acid (pH 7.4) for 21 min, dried and visualized by using TEM. Bar represents 100 nm.
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centage of degraded tqON after the ExoI addition in the samples
containing either tqON or tqONþCANC (Fig. 2C); tqON or
tqONþΔMACANCSP2 (Fig. 2F). The portion of residual tqON that
remained protected by the CANC assemblage during ExoI cleavage
was about 60% and in the case of ΔMACANCSP2, it was about 58%.
The combined standard deviation of all these aforementioned
experiments was less than 5% (Fig. 2C and F).
Validation of FAITH using known assembly inhibitors
The sensitivity of FAITH was validated using a CAI inhibitory
peptide (ITFEDLLDYYGP) and its inactive derivative CAIctrl (IYDP-
TLYGLEFD), earlier published by Sticht et al. (2005). We performed
the reaction in 96-well plate by mixing the CANC orΔMACANCSP2
proteins with CAI or CAIctrl usually in an equimolar ratio. After 1 h
incubation at 4 °C, the mixture was diluted in the assembly buffer
containing the tqON and was incubated three hours. Then, the
ExoI was added and the ﬂuorescence was measured for 120 t
35 min. The level of inhibition was calculated as a percentage of
the increased ﬂuorescence ranging between controls represented
with free tqON and that bound in the particles assembled in the
absence of inhibitor. The efﬁciency of inhibitors was calculatedfrom three independent measurements with three repetitions for
each compound. Aliquots of the samples were negatively stained
and analyzed by TEM.
The control measurements indicated that neither CAI nor
CAIctrl affected the activity of ExoI as shown for the samples
containing mere tqON (Fig. 3A and E red curves), tqONþCAI
(Fig. 3A and E orange curves) and tqONþCAIctrl (Fig. 3A and E
brown curves). As expected, the addition of the inactive inhibitor,
CAIctrl to the CANCþtqON or ΔMACANCSP2þtqON samples did
not affect the assembly as the emitted ﬂuorescence time curve
(Fig. 3A and E pink curves) almost copied those obtained for
CANCþtqON and ΔMACANCSP2þtqON samples (Fig. 3A and E
blue curves). In contrast, an equimolar concentration of CAI to the
CANCþtqON sample (Fig. 3A green curve) efﬁciently inhibited the
assembly resulting in a release of ﬂuorescence signal similar to
that of tqON alone. Unlike for CANC, the addition of CAI to
ΔMACANCSP2þtqON sample in an equimolar ratio resulted in a
lower increase of ﬂuorescence (Fig. 3E dark green curve). However,
more efﬁcient inhibition was achieved with the molar ratio of
protein to inhibitor of 1:5 (Fig. 3E light green curve). The inhibitory
effect of the CAI peptide was further conﬁrmed by TEM analyses.
The efﬁcient assembly of the CANC tubular particles was observed
in the presence of the inactive CAIctrl (Fig. 3B) while only the free,
R. Hadravová et al. / Virology 486 (2015) 78–8784non-assembled protein was detected in the presence of the equi-
molar concentration of the active inhibitor CAI (Fig. 3C). Similarly,
the inhibitory effect on the assembly of the ΔMACANCSP2
immature-like spherical particles was observed for CAI (Fig. 3G),
but not for CAIctrl (Fig. 3F); both used at the molar ratio protein to
inhibitor of 1:1 and 1:5.
To further evaluate the effectiveness of the FAITH, several
inhibitors with different proposed modes of action were measured
(Fig. 3D and H). We tested the derivatives of thioesters known to
possess antiviral activity by zinc ejection from the NC zinc-binding
domain labelled 19, 89 and 247 (Srivastava et al., 2004). Two other
compounds, reported to block HIV-1 assembly were tested:
PF3450074 (PF74) with the proposed effect both on assembly and
uncoating of mature core (Blair et al., 2010; Lemke et al., 2012; Shi
et al., 2011) and BM2, which upon binding, protrude from CANTD
and prevent interactions with the neighbouring CACTD thus
destabilizing the CANTD/CACTD interface in mature core (Blair et
al., 2010; Lemke et al., 2012; Shi et al., 2011). The thioester deri-
vatives had no effect on the assembly of both types of particles at a
1:1 or 1:5 ratios. The BM2 compound, at an equimolar (or higher)
ratio, inhibited the HIV-1 mature particle, as well as the immatureFig. 5. TEM analysis of assembled ΔMACANCSP2 particles in the presence of indicated inhibi
indicated inhibitors or DMSO, the mixtures were diluted to the concentration optimal f
Then Exonuclease 1 and MgCl2 were added and emitted ﬂuorescence was measured by
with 2% phosphotungstic acid (pH 7.4) for 21 min, dried and visualized by using TEMparticle formation. However, the addition of PF74 affected the
formation of neither the mature nor immature HIV-1 particles,
which is consistent with the later published results, indicating that
it rather than blocking the assembly, triggers premature uncoating
in the target cells (Blair et al., 2010; Bhattacharya et al., 2014).
Following ﬂuorescence measurement, the samples were analyzed
by TEM (Figs. 4 and 5).Discussion
Despite the continuing need for new HIV inhibitors that would
overcome the problem with emerging drug resistant strains, no
FDA approved assembly inhibitor has yet been released. One of the
reasons for this is very likely related to a methodical gap, i.e. the
absence of an effective method for the screening of such com-
pounds. In contrast, there is a broad spectrum of methods for
enzymatic activity measurements available, and thus it is not
surprising that the currently used anti-HIV drugs are inhibitors of
reverse transcriptase, protease and integrase.tors. Following one-hour incubation of HIV ΔMACANCSP2 protein in the presence of
or assembly, tqON was added and the incubation proceeded for three-hours at RT.
ﬂuorescence reader. 10 ml aliquots of the reaction mixture were negatively stained
. Bar represents 100 nm.
R. Hadravová et al. / Virology 486 (2015) 78–87 85Lanman and Prevelige (2005) reported a method suitable for
the high-throughput screening, which is based on monitoring the
HIV-1 CA assembly kinetics by turbidity measurement. However, a
high HIV-1 CA protein concentration (38-400 μM) and high NaCl
concentration might affect protein interactions (1–2.25 M) and
limit suitability of this method for screening under physiological
conditions. Another high-throughput screening (HTS) method,
using much lower protein and salt concentration, was reported by
Lemke et al. (2012). This efﬁcient HTS assay is based on the ability
of NC to bind tightly to TG rich oligonucleotides, which are labelled
by both biotin- and ﬂuorescein. The biotin-labelled oligonucleo-
tides are bound to the microplate surface and serve as a nucleation
centre for CANC polymerization. The remaining unbound material
is then washed away and the ﬂuorescence is measured. The main
drawback of the HTS assay is that mere interaction of the com-
ponents, instead of the assembly might produce false positive
results. Moreover, the polymerization of CANC on immobilized
“scaffold-like” nucleic acid excludes direct conﬁrmation of the
assembled structures by EM. Also, the washing steps somehow
complicate the HTS method.
The FAITH combines an improved protocol for the in vitro
assembly with the usage of a dually labelled TaqMan-based oli-
gonucleotide. We simpliﬁed the in vitro assembly of HIV-1 CA to a
mere dilution of the protein from the stock solution to the
assembly buffer in the presence of labelled oligonucleotide and
subsequent addition of the exonuclease. The FAITH sensitivity is
achieved by measurement of ﬂuorescence signal released upon
separating a single terminal nucleotide carrying the ﬂuorescence
label (FAM) from its quencher (BHQ). The principally fundamental
difference of FAITH from the aforementioned methods is that the
mere interaction of a protein with the nucleic acid is not sufﬁcient
for tqON protection against nucleases shown in the presence of
CAI or BM2 inhibitors that both efﬁciently block the assembly but
not the interaction of tqON with NC as indicated by an electro-
phoresis mobility shift assay (data not shown).
The model represented by CANC is distinct from the mature
core assembled from mere CA and we are aware of such potential
limitation. However, the fact that CANC assembles in tubular
morphology and is sensitive to inhibitors of mature core assembly
justiﬁes its application as a model for a mature core consisting of
both CA and NC with bound nucleic acid.
The published X-ray structure of the complex of the peptide
inhibitor CAI with the HIV-1 CTD-CA shows that the α-helical CAI
binds into the conserved hydrophobic groove of CTD-CA (formed
by helices 1, 2 and 4), This interaction induces formation of a
compact ﬁve helix bundle and alters dimeric interaction of CA-CTD
(Ternois et al., 2005). In the in vitro assembly assays, it was shown
that addition of an equimolar concentration of CAI to HIV-1 CANC
protein efﬁciently abolished its assembly into tubular structures,
whereas to prevent the assembly of immature particles, a ﬁve-fold
molar excess of CAI was required (Sticht et al., 2005). We used CAI
and its inactive control CAIctrl to validate our assay. Experimental
data satisfactorily conﬁrmed the ﬁdelity of FAITH, as documented
by the method itself as well as veriﬁed by TEM analysis the
assembled particles (Figs. 4 and 5).
Apart from CAI peptide inhibitor, the TEM analysis conﬁrmed
also the activity of BM2 in blocking mature and immature
assembly (Figs. 4 and 5). BH2 is one of the active benzimidazole
compounds, shown to be a “bonaﬁde” capsid assembly inhibitor
binding to a pocket located at the base of the central four-helix
bundle of the NTD-CA (Lemke et al., 2012). In order to verify
whether this inhibitor of mature core assembly may bind also into
immature CA lattice, an X-ray structure of a CA protein fragment
complexed with one of the benzimidazole derived compounds
BM4 (PDB ID: 4E92) was superimposed onto cryoEM-based
structures of both immature and mature HIV-1 CA (PDB IDs:4USN and 3J4F, respectively). Despite big differences in overall
architecture of mature and immature CA lattices, the region
deﬁning the binding pocket of BM4 superimposes well with both
types of lattices (data not shown). This can rationalize the fact that
BM2 can bind to both types of lattices. Another inhibitor showing
the expected FAITH results was PF74 inhibitor published to inter-
fere with both the viral uncoating process and the formation of
infectious particles (Blair et al., 2010). It did not abolish the in vitro
assembly of either CANC (Fig. 4) orΔMACANCSP2 (Fig. 5), which is
consistent with the features of published co-crystal structure
showing a novel binding pocket in the NTD-CA (Blair et al., 2010).
This binding pocket between helices 3 and 4 is preformed in the
hexamer and the binding PF74 to this site signiﬁcantly increases
the rate of CA assembly in in vitro studies (Blair et al., 2010;
Bhattacharya et al., 2014). Interestingly, the presence of PF74 in the
ΔMACANCSP2 assembly reaction affected structure of the parti-
cles and instead of spherical particles, a mixture of short rod-like
or conical structures was observed (Fig. 5). It can be hypothesized,
that binding of this compound shifted the equilibrium towards the
conditions favoring mature-like assembly. It must be however
noted that also the morphology of the mature-like CANC particles
formed in the presence of PF74 differs from that assembled
without the inhibitor (Fig. 4).
The results clearly demonstrate that the FAITH can be used for
the testing of two types of HIV assembly inhibitors: i) those
interfering with protein–protein interactions and ii) those blocking
nucleic acid–protein interactions between tqON and NC. The
advantage of this method is not only in its format, but also in its
high sensitivity and simplicity as it is based on the pipetting of
three solutions without any washing step.Conclusions
The main advantages of the FAITH over the published methods
are: i) the whole procedure is carried out under physiological
conditions; ii) the assay's simplicity and nonobligatory washing
steps, and iii) the assay is not affected by DMSO to a ﬁnal
concentration of 1%.
The high-throughput ﬂuorescent method described here can
broaden the opportunities for teams and companies searching for
new types of viral inhibitors, i.e. those targeting the particle
assembly or incorporation of a genomic nucleic acid.Material and methods
Construct preparation
Preparation of expression vectors for HIV-1 CANC was descri-
bed previously (Ulbrich et al., 2006). ΔMACANCSP2, encoding the
deletion of 16-99 amino acid within MA, was constructed by
inserting the ClaI-XhoI PCR fragment obtained from the pSAX2
vector (Rumlova et al., 2014) into the HIV-1 Δp6Gag pET expres-
sion vector. The whole HIV speciﬁc region was veriﬁed by
sequence analysis.
Protein expression and puriﬁcation
The HIV-1 CANC protein was puriﬁed as published previously
(Campbell and Vogt, 1995; Ulbrich et al., 2006) with some mod-
iﬁcation. The HIV-1 CANC protein was expressed in Escherichia coli
BL21 (DE3). The bacterial pellet (5 g) was resuspended in 25 ml of
buffer D (20 mM Tris–HCl, pH 8, 0.5 M NaCl, 10% glycerol, 1 mM
EDTA, 10 mM DTT, 1 mM Triton X-100, 1 mM PMSF) and the cells
were disrupted by sonication (420 s) on ice. To the cell lysate,
R. Hadravová et al. / Virology 486 (2015) 78–8786polyethyleneimine to a ﬁnal concentration 0.3% (w/v), was added
and cell debris and nucleic acids were removed by ultracentrifuga-
tion (Beckman, TI 90, 55,000 rpm, 3 h, 4 °C). The HIV CANC protein
was precipitated from the supernatant by ammonium sulphate (ﬁnal
concentration 25% (w/v)) at 4 °C. The precipitated protein was cen-
trifuged (15,000 rpm, 15 min, 4 °C), resuspended in buffer E (20 mM
Tris–HCl, pH 8.0, 0.1 M NaCl, 50 mM ZnCl2, 10 mM DTT, 1 mM PMSF)
and dialyzed overnight against the same buffer at 4 °C. The pre-
cipitate was removed by low speed centrifugation and the cleared
supernatant was loaded on a DEAE cellulose column (bed volume
40 ml, ﬂow rate 0.5 ml/min) in buffer E. The ﬂow-through and
washing fractions were pooled and loaded on the top of a phos-
phocellulose column (bed volume 50 ml, ﬂow rate 0.5 ml/min). The
bound proteins were eluted by a NaCl gradient from 0.1 M to 1 M
NaCl in the buffer E. The fractions containing CANC protein were
pooled and dialyzed overnight against a storage buffer (buffer E
containing 0.5 M NaCl) at 4 °C. The proteins were concentrated to
approximate volume of 5 ml and loaded on the top of Sephadex
G-100 column (bed volume 470 ml, ﬂow rate 0.1 ml/min) equili-
brated in the buffer E with 0.5 M NaCl (storage buffer). The HIV CANC
protein from pooled fractions were concentrated to 2–4 mg/ml and
stored at 80 °C. The purity of the protein was analyzed by SDS-
PAGE (Fig. 1 A). The expression/puriﬁcation process ofΔMACANCSP2
protein was similar as that described above, only the step of poly-
ethylenimine and ammonium sulphate precipitation was omitted.
The purity of the protein was analyzed by SDS-PAGE (Fig. 1D).
In vitro assembly by dialysis
An aliquot of 60 mg of puriﬁed HIV CANC or ΔMACANCSP2
protein was mixed with 40-mer oligonucleotide ON or FAM-BHQ
modiﬁed ON (tqON) (Fig. 1G) in a ﬁnal protein: oligonucleotide
10:0.5 (wt/wt) ratio, which corresponds to molar ratios 7.5:1 and
8:1 for HIV CANC:tqON and ΔMACANCSP2:tqON, respectively. The
ﬁnal reaction volume was adjusted to 100 ml by the storage buffer
(20 mM Tris–HCl, pH 8.0, 0.5 M NaCl, 50 mM ZnCl2, 10 mM DTT,
1 mM PMSF) and the mixture was dialyzed against the assembly
buffer (50 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM ZnCl2) for 3 h
at room temperature. The dialysate was used for TEM.
In vitro assembly by dilution
Puriﬁed HIV-1 CANC or ΔMACANCSP2 protein in the storage
buffer (20 mM Tris–HCl, pH 8.0, 0.5 M NaCl, 50 mM ZnCl2, 10 mM
DTT, 1 mM PMSF) was rapidly diluted by the assembly buffer
(50 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM ZnCl2) in 96-well
plate format so that the ﬁnal concentration of NaCl was 300 mM,
CANC protein 18 mM (60 mg/100 ml) and ΔMACANCSP2 protein
15 mM (60 mg/100 ml). Immediately after the dilution, the 40-mer
oligonucleotide ON or FAM-BHQ modiﬁed ON (tqON) was added
(Fig. 1G) at the ﬁnal protein:ON ratio usually 10:0.5 in a ﬁnal
sample volume of 100 ml and was incubated 3 h at room tem-
perature. The samples were used for TEM.
Inhibition of in vitro assembly
The inhibitor was added to the HIV CANC or ΔMACANCSP2
protein in the storage buffer (20 mM Tris–HCl, pH 8.0, 0.5 M NaCl,
50 mM ZnCl2, 10 mM DTT, 1 mM PMSF) typically in the ﬁnal molar
ratio protein:inhibitor 1:1, 1:2 or 1:5, and the mixture was incu-
bated for 1 h on ice. Then the mixture was rapidly diluted with the
assembly buffer (50 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM
ZnCl2) so that the ﬁnal concentration of NaCl was 0.3 M, CANC
protein 18 mM (60 mg/100 ml), ΔMACANCSP2 protein 15 mM (60 mg/
100 ml) and the procedure continued as described above.Optionally, if the inhibitor was solubilized in DMSO, the ﬁnal
concentration of DMSO was up to 1%.
Fluorescence measurement
Following the one-hour incubation of HIV CANC and ΔMA-
CANCSP2 protein in the presence of inhibitor (as described above),
the mixtures were diluted a ﬁnal sample volume of 100 ml by the
assembly buffer (50 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM
ZnCl2) to a ﬁnal concentration of NaCl 0.3 M, CANC protein 18 mM
(60 mg/100 ml), and ΔMACANCSP2 protein 15 mM (60 mg/100 ml),
DMSO up to 1%, tqON was added and the incubation proceeded for
three-hour at RT. To the 100 ml of reaction mixtures in the 96-well
plate, 20 U/ml of Exonuclease 1 (NEB) and MgCl2, to a ﬁnal con-
centration of 6.7 mM, were added and emitted ﬂuorescence was
immediately measured by ﬂuorescent reader (Tecan Inﬁnite
M1000) for 120 min. The excitation and emission wavelengths
corresponded to 495 nm and 520 nm, respectively.
Electron microscopy
Particles formed during assembly reaction were visualized by
negative staining. Parlodion-carbon-coated grids were ﬂoated on
the top of 5 ul drop of the sample, washed in distilled water and
transferred on the top of drop 2% phosphotungstic acid (pH 7.4),
stained for 21 min and dried. Photomicrographs were taken
with a JEOL JEM-1200EX electron microscope operated at 60 kV.Authors' contributions
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